Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GNCA Genocea Biosciences
0.0010.0000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Total revenue
270K 20.75% 1.64M 0 262.25% 1.64M
Operating revenue
-- 270K 20.75% 1.64M -- 0 262.25% 1.64M
Cost of revenue
Gross profit
Operating expense
29.15% 16.04M 11.14% 53.73M 14.47% 13.41M 19.34% 13.36M
Selling and administrative expenses
-1.96% 3.6M 2.27% 14.71M -19.37% 3.13M 6.59% 3.88M
-General and administrative expense
-1.96% 3.6M 2.27% 14.71M -19.37% 3.13M 6.59% 3.88M
Research and development costs
42.20% 12.44M 14.90% 39.02M 31.21% 10.28M 25.50% 9.47M
Operating profit
-26.98% -15.77M -10.86% -52.09M -14.47% -13.41M -9.10% -11.72M
Net non-operating interest income expense
17.20% -231K 18.77% -1.12M 23.08% -290K
Non-operating interest expense
-17.20% 231K -18.77% 1.12M -- -- -23.08% 290K
Other net income (expense)
-96.38% 26K 330.03% 20.02M 103.94% 129K 27.79% 8.38M
Gain on sale of security
-98.71% 11K 126.57% 20.14M -- -- -22.15% 8.38M
Other non- operating income (expenses)
111.03% 15K 97.12% -122K 103.94% 129K 100.05% 2K
Income before tax
-33.34% -15.98M 24.06% -33.2M 11.38% -13.28M 20.48% -3.62M
Income tax
Net income
-33.34% -15.98M 24.06% -33.2M 11.38% -13.28M 20.48% -3.62M
Net income continuous Operations
-33.34% -15.98M 24.06% -33.2M 11.38% -13.28M 20.48% -3.62M
Minority interest income
Net income attributable to the parent company
-33.34% -15.98M 24.06% -33.2M 11.38% -13.28M 20.48% -3.62M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-33.34% -15.98M 24.06% -33.2M 11.38% -13.28M 20.48% -3.62M
Basic earnings per share
-22.22% -0.22 51.02% -0.48 17.39% -0.19 37.50% -0.05
Diluted earnings per share
-22.22% -0.22 56.76% -0.48 17.39% -0.19 80.77% -0.05
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion with Explanation----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
CEO: Mr. William D. Clark
Market: Pink Market
Listing Date: 02/05/2014
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist